CellaVision
227.5 SEK +0.89%1,503 investors are following this company
CellaVision is active in medical technology. The company's operations develop and market image analysis systems for diagnosing blood and other body fluids. The products are intended to replace traditional microscope analysis. Operations are conducted on a global level, primarily in the Nordic countries, Europe and North America, where customers consist of research institutes. The head office is located in Lund.
Revenue
677.29M
EBIT %
24.66 %
P/E
41.67
Dividend yield-%
0.99 %
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
CEVI
Daily low / high price
222.5 / 229
SEK
Market cap
5.43B SEK
Turnover
1.25M SEK
Volume
5.5K
Latest videos
Financial calendar
General meeting
03.05.2024
Annual dividend
06.05.2024
Interim report
19.07.2024
Interim report
24.10.2024
Annual report
06.02.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
William Demant Invest | 19.9 % | 19.9 % |
Grenlunden CEVI AB | 10.0 % | 10.0 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
CellaVision, Audiocast with teleconference, Q1, 2024
A Solid Start to the Year
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools